NEUROSTAR TMS THERAPY SYSTEM 81-61000-000

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a 05 report with the FDA on 2015-05-26 for NEUROSTAR TMS THERAPY SYSTEM 81-61000-000 manufactured by Neuronetics, Inc..

Event Text Entries

[5829748] The treating physician contacted neuronetics on (b)(6) 2015 to report the (b)(6) 2015 hospitalization of a patient for suicidal ideation. The patient is a (b)(6) y/o woman with life-long recurrent major depression (mdd). Her baseline symptom scores were phq9-22, madrs-27. Her first tms treatment was on (b)(6) 2014. She did well during her first two weeks of tms therapy with improvement in her symptom scores and increased energy, but also had racing thoughts. The following week, she began to have symptom worsening, crying, and expressed that she did not want to continue living. She continued tms treatment, but by (b)(6) 2014, her symptom scores were phq9-19 and madrs-21. On (b)(6) 2015, the patient expressed a plan to kill herself with a gun available in her house, so her physician had her hospitalized. She was discharged on (b)(6) 2015, no longer suicidal; her pristiq and lithium were discontinued and substituted with viibryd 40mg/d.
Patient Sequence No: 1, Text Type: D, B5


[13419045] The treating physician believes this event is device related. Neuronetics believes that the patient's suicidal ideation and subsequent hospitalization is probably not device related but rather consistent with her current depressive episode. The factors favoring this event being consistent with her current depressive episode include a prior history of suicidal ideation, a history of ineffective response to treatment with pharmacotherapy in this and prior depressive episodes, the patient's report on admission to the hospital that her current depressive episode had begun in (b)(6) 2014 and the patient's report that she had not responded to medications or her 31 tms treatment sessions. The neurostar tms therapy system labeling informs that patients who have major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior and that patients should be observed closely for worsening symptoms and signs of suicidal behavior and/or unusual behavior. If worsening of symptoms continues,consideration should be given to changing the therapeutic regimen, including discontinuation of treatment with the neurostar tms therapy. The device history records and service records were reviewed and it was confirmed that there were no device malfunctions and the device was functioning as intended.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number3004824012-2015-00001
MDR Report Key4797234
Report Source05
Date Received2015-05-26
Date of Report2015-05-26
Date of Event2015-01-02
Date Mfgr Received2015-04-26
Device Manufacturer Date2012-11-01
Date Added to Maude2015-05-27
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA0
Event Location0
Manufacturer ContactDR. JUDY WAYS
Manufacturer Street3222 PHOENIXVILLE PIKE
Manufacturer CityMALVERN PA 19355
Manufacturer CountryUS
Manufacturer Postal19355
Manufacturer Phone6109814107
Manufacturer G1NEURONETICS, INC.
Manufacturer Street3222 PHOENIXVILLE PIKE
Manufacturer CityMALVERN PA 19355
Manufacturer CountryUS
Manufacturer Postal Code19355
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameNEUROSTAR TMS THERAPY SYSTEM
Generic NameTRANSCRANIAL MAGNETIC STIMULATION
Product CodeOBP
Date Received2015-05-26
Model Number81-61000-000
OperatorHEALTH PROFESSIONAL
Device AvailabilityY
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerNEURONETICS, INC.
Manufacturer Address3222 PHOENIXVILLE PIKE MALVERN PA 19355 US 19355


Patients

Patient NumberTreatmentOutcomeDate
101. Hospitalization 2015-05-26

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.